Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Pembrolizumab

5

XV.bb Path: Airway inflammation

1
Last update : 21/10/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5

Publications

Bronchiolitis of immune checkpoint inhibitor therapy-related pneumonitis.
The American journal of the medical sciences 2023 Mar;365;e31-e32 2023 Mar
Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Jan;14;e9-e10 2019 Jan
Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators.
Respiratory medicine case reports 2019;28;100866 2019
Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
Respiratory medicine case reports 2016;19;118-20 2016

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies